Skip to main content
. 2022 Aug 27;12:14640. doi: 10.1038/s41598-022-18729-0

Table 1.

Patient characteristics and baseline data.

Characteristic Dexmedetomidine group Control group Z or χ2 P value
Total patients, no. 54 52 NA NA
Age, mean (SD), year 46.89 (3.71) 46.71 (3.66) 0.248 0.805
BMI, mean (SD) 26.59 (2.13) 26.02 (2.19) 1.374 0.172
ASA classification (n, %) 1.608& 0.301
I 44 (81.5) 38 (73.1)
II 10 (18.5) 14 (26.9)
Time, mean (SD), min
Surgical 76.83 (19.25) 74.13 (20.17) 0.705 0.482
Anesthetic 83.69 (20.84) 80.71 (21.90) 0.716 0.475
Hypertension (Y/N) 21/43 26/26 1.325& 0.250
Mellitus (Y/N) 12/42 12/40 0.011& 0.916
Use of vasoactive drugs (n, %) 6 (11.1) 9 (17.3) 0.837& 0.360
Tramadol (IQR), mg 0 (0–100) 0 (0–100) − 1.310 0.190
Bleeding, ml# 57.79 (9.66) 57.28 (8.90) 0.282 0.778
Crystalloid solution, ml# 1087.41 (157.35) 1069.23 (146.08) 0.616 0.539
Urine output, ml# 365.74 (50.31) 363.46 (47.61) 0.239 0.812

NA not applicable, ASA American society of anesthesiologists, BMI body mass index, SD standard deviation, n number, Y yes, N no.

#Values were rounded to the nearest 10 mL.

&χ2 value.